Given that ZDHHC3 potentially positively regulates the activities of mutant TP53, thus inhibiting ZDHHC3 may sensitize pancreatic tumors to anti-tumor treatments, including immunotherapy. Here, TP53 is linked to pancreatic neoplasm.